Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

NCT05895643 is registered in ClinicalTrials.gov with Psychiatric Centre Rigshospitalet as lead sponsor.

NCT NCT05895643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05895643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
Lead sponsor
Psychiatric Centre Rigshospitalet
Phase
Phase 2
Overall status
Completed
Start date
June 13, 2023
Completion date
July 31, 2025
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol abuse, alcohol addiction, alcohol dependence, alcohol use disorder